Anti-HIF-1 alpha antibody [EP1215Y],Abcam,AB51608
Anti-HIF-1 alpha antibody [EP1215Y] (ab51608) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in ChIC/CUT&RUN-seq, Flow Cyt (Intra), ICC/IF, IHC-P, IP, WB in human samples. Anti-HIF-1 alpha antibody [EP1215Y] (ab51608) has been cited over 340 times in peer reviewed journals and is trusted by the scientific community. Abcams high quality manufacturing and validation processes ensure Anti-HIF-1 alpha antibody [EP1215Y] (ab51608) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility. The specificity of Anti-HIF-1 alpha antibody [EP1215Y] (ab51608) has been confirmed by testing in knockout samples. Anti-HIF-1 alpha antibody [EP1215Y] (ab51608) has 12 independent reviews from customers. Anti-HIF-1 alpha antibody [EP1215Y] (ab51608) specifically detects HIF-1 alpha (UniProt ID: Q16665; Molecular weight: 93kDa) and is sold in 100 uL and 1 mL selling sizes. Conjugation-ready, carrier free format available for antibody clone EP1215Y - ab2173 . Antibody clone EP1215Y is also available pre-conjugated to a variety of labels for your convenience - Alexa Fluor® 647 ( ab19569 ). HIF-1 alpha, also known as hypoxia-inducible factor 1-alpha (HIF1A), is a critical regulator of cellular response to low oxygen levels. HIF1A is a transcription factor commonly referred to as a "master regulator of the hypoxic response" for its central role in the regulation of cellular adaptations to hypoxia. Hypoxia contributes to the pathophysiology of human disease, including myocardial and cerebral ischemia, cancer, pulmonary hypertension, congenital heart disease and chronic obstructive pulmonary disease. A highly specific HIF-1 alpha antibody, essential for studying hypoxia-inducible factors and oxygen homeostasis. This antibody is crucial in tumor hypoxia research, particularly in understanding cancer progression and angiogenesis. It is widely used in studies of metastasis and HIF-1 alpha inhibitors. The HIF1A molecular weight is approximately 120 kDa, and detecting it accurately is essential for understanding its role in the tumor microenvironment. Elevated HIF-1 alpha levels are linked to tumor progression, angiogenesis, and metastasis. Monitoring HIF-1 alpha can provide valuable insights into cancer biology and potential therapeutic targets. This antibody is also validated for CUT&RUN-seq, which is a key application to map protein-DNA interactions on a genome-wide scale using NGS. For Mouse specific Hif-1-alpha rabbit monoclonal antibody, please see ab179483 (clone ID: EPR16897). ab179483 has been confirmed for Mouse sample in WB. We have mixed customer feedback towards the rat specificity so we are unable to confirm and guarantee its performance with rat samples. Please contact technical team for more information. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .
Host
Rabbit
Reactivity
Human
Application
ICC/IF, WB, Flow Cyt (Intra), IHC-P, ChIC/CUT&RUN-seq, IP
Platform ID
BAB142841961
Abcam
Contact
Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215
Email:
Specifications
Scientific Background
Target data Functions as a master transcriptional regulator of the adaptive response to hypoxia (PubMed : 11292861, PubMed : 11566883, PubMed : 15465032, PubMed : 16973622, PubMed : 17610843, PubMed : 18658046, PubMed : 20624928, PubMed : 22009797, PubMed : 30125331, PubMed : 9887100). Under hypoxic conditions, activates the transcription of over 40 genes, including erythropoietin, glucose transporters, glycolytic enzymes, vascular endothelial growth factor, HILPDA, and other genes whose protein products increase oxygen delivery or facilitate metabolic adaptation to hypoxia (PubMed : 11292861, PubMed : 11566883, PubMed : 15465032, PubMed : 16973622, PubMed : 17610843, PubMed : 20624928, PubMed : 22009797, PubMed : 30125331, PubMed : 9887100). Plays an essential role in embryonic vascularization, tumor angiogenesis and pathophysiology of ischemic disease (PubMed : 22009797). Heterodimerizes with ARNT; heterodimer binds to core DNA sequence 5'-TACGTG-3' within the hypoxia response element (HRE) of target gene promoters (By similarity). Activation requires recruitment of transcriptional coactivators such as CREBBP and EP300 (PubMed : 16543236, PubMed : 9887100). Activity is enhanced by interaction with NCOA1 and/or NCOA2 (PubMed : 10594042). Interaction with redox regulatory protein APEX1 seems to activate CTAD and potentiates activation by NCOA1 and CREBBP (PubMed : 10202154, PubMed : 10594042). Involved in the axonal distribution and transport of mitochondria in neurons during hypoxia (PubMed : 19528298).. (Microbial infection) Upon infection by human coronavirus SARS-CoV-2, is required for induction of glycolysis in monocytes and the consequent pro-inflammatory state (PubMed : 32697943). In monocytes, induces expression of ACE2 and cytokines such as IL1B, TNF, IL6, and interferons (PubMed : 32697943). Promotes human coronavirus SARS-CoV-2 replication and monocyte inflammatory response (PubMed : 32697943). See full target information HIF1A
Category Paths
- Products>Primary Antibodies>Monoclonal Antibodies
- Products>Primary Antibodies>IHC Antibodies
- Products>Primary Antibodies>Recombinant Antibodies
Please provide the required information below so that we can quickly source your products.